MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA   Report issue

For profit Phase 3
Founded: Sao Paulo Brazil (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2017
NCT02961634
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

ciclopirox (loprox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Onychomycosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1